GH
GH clinical trials: Guardant Health, Inc.
Every trial on ClinicalTrials.gov where Guardant Health, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 27
- Trials linked
- 10
- As lead sponsor
- 17
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
GH on the catalyst calendar · GH registry changes
- Primary completion Dec 2027Sponsor estimateNo phase registeredNCT07620535Decision Counseling and Follow-up for Shield+ PatientsGuardant Health, Inc. · Colo-rectal CancerRecruitingGHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 1, 2030Sponsor estimateNo phase registeredNCT06880055Shield Post-Approval Study ProtocolGuardant Health, Inc. · Colo-rectal CancerRecruitingGHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2030Sponsor estimateNo phase registeredNCT05059444ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy EvaluationGuardant Health, Inc. · Bladder CarcinomaRecruitingGHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2030Sponsor estimateNo phase registeredNCT05935384SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuationGuardant Health, Inc. · Non-small Cell Lung CancerRecruitingGHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT05117840Screening for High Frequency Malignant DiseaseGuardant Health, Inc. · Lung CancerActive, not recruitingGHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 20, 2024ActualNo phase registeredNCT04136002Evaluation of the ctDNA LUNAR Test in an Average Patient Screening EpisodeGuardant Health, Inc. · Colorectal CancerActive, not recruitingGHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 17, 2022ActualNo phase registeredNCT04436393Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Breast CancerGuardant Health, Inc. · Advanced Breast CancerCompletedGHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 23, 2020ActualNo phase registeredNCT03615443Noninvasive vs. Invasive Lung EvaluationGuardant Health, Inc. · Non-Small Cell Lung CancerCompletedGHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 1, 2020ActualNo phase registeredNCT03625557Guardant360® Test-Related Clinical Outcomes in Patients Who Share Medical RecordsGuardant Health, Inc. · Non-Hematologic MalignancyCompletedGHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 1, 2019ActualNo phase registeredNCT03477474Registry of Guardant360® Use and Outcomes In People With Advanced CancerGuardant Health, Inc. · Non-small Cell Lung Cancer MetastaticTerminatedGHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 1, 2027Sponsor estimateNo phase registeredNCT07436637Guardant Shield Colorectal Cancer ScreeningUniversity of Miami · Colorectal CancerActive, not recruitingGHCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2030Sponsor estimateNo phase registeredNCT03774758Biomarkers for Risk Stratification in Lung CancerUniversity of California, San Francisco · Nodule Solitary PulmonaryRecruitingGHCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2027Sponsor estimatePhase 2NCT04410796Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung CancersMemorial Sloan Kettering Cancer Center · Metastatic Non-small Cell Lung CancerRecruitingAZNCollaboratorGHCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 30, 2034Sponsor estimatePhase 3NCT07802626Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA TestingSWOG Cancer Research Network · HR Positive/HER-2 Negative Breast CancerNot yet recruitingAZNCollaboratorGHCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 1, 2028Sponsor estimatePhase 3NCT07004413Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC PatientsCharite University, Berlin, Germany · Colorectal Cancer MetastaticNot yet recruitingGHCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 18, 2025ActualNo phase registeredNCT06444542Understanding Patient Preference on Colorectal Cancer Screening Options-PSUMilton S. Hershey Medical Center · Colo-rectal CancerCompletedGHCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2025ActualNo phase registeredNCT06119425Blood-Based Colorectal Cancer (CRC) Screening Implementation Into Clinical Practice HighlandsBallad Health · Cancer ColonCompletedGHCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 28, 2026Sponsor estimateNo phase registeredNCT05885009Feasibility and Impact of Liquid Biopsy Genomic Profiling on Treatment Patients With Metastatic Prostate Cancer in Spain (SOLTI-2102)SOLTI Breast Cancer Research Group · Metastatic Prostate Cancer
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 30, 2023ActualNo phase registeredNCT04497285Real World Study Using Comprehensive Genomic Data on the Next Treatment Decision Making in Metastatic Breast CancerSOLTI Breast Cancer Research Group · Metastatic Breast CancerActive, not recruitingNVSCollaboratorGHCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2024ActualNo phase registeredNCT05716477Blood Test (Guardant Shield™) for Screening of Colorectal Cancer in Underserved PatientsOhio State University Comprehensive Cancer Center · Colorectal CarcinomaCompletedGHCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 15, 2024Sponsor estimatePhase 2NCT04259944Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS TrialIFOM ETS - The AIRC Institute of Molecular Oncology · Colon CancerUnknown statusGHCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 1, 2024Sponsor estimateNo phase registeredNCT05703243Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Liquid Molecular Testing Panel in the Community Setting...Glendale Adventist Medical Center d/b/a Adventist Health Glendale · Stage III Solid TumorsUnknown statusGHCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2023Sponsor estimateNo phase registeredNCT05641870Molecular Profiling and Dynamic Changes of ctDNA in Unresectable Locally Advanced NSCLCParc de Salut Mar · Lung CancerUnknown statusGHCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2021Sponsor estimateNo phase registeredNCT03791034Cell Free DNA for the Diagnosis and Treatment in Early NSCLCSamsung Medical Center · Non-small Cell Lung CancerRecruitingGHCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2017ActualNo phase registeredNCT03248089Spanish Lung Liquid vs. Invasive Biopsy Program (SLLIP)MedSIR · Lung CancerCompletedGHCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 2 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner